Individuals infected with HIV should start antiretroviral therapy (ART) at diagnosis to lower their risk of developing AIDS or other health issues related to HIV infection, according to findings from an interim review of the first large-scale randomized clinical trial of early treatment, the Strategic Timing of Antiretroviral Treatment (START) trial, (http://1.usa.gov/1cZVa0l). The START study was initiated in 2009 to determine the most propitious point at which to begin ART for HIV—either early in the course of infection, when the CD4+ cell count is greater than 500 cells/mm3, or later, when it drops below 350 cells/mm3.
Friedrich MJ. Study Reveals Benefit of Early Antiretroviral Treatment. JAMA. 2015;314(3):216. doi:10.1001/jama.2015.8118
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: